Road to recovery: What COVID-19 means for medtech in China and around the world

Posted by Tim Lee on May 4, 2020

Access COVID-19 resources

Given the increasing toll that COVID-19 lockdowns are imposing on economies, many markets that have seen their peaks are beginning preparations to reopen. As the first market impacted by COVID-19 and the first to institute a gradual reopening since March, China is two months ahead of all other major markets in their recovery journey. We spoke to several medtech executives across different spaces to get a glimpse of what the future may look like in China, as well what it may mean for other markets.


>
Read More

The Shakeout of 2020: The Year That Small Changes Emerge From the Big Hype

Posted by Brian Chapman on January 13, 2020

With a new year and a new decade underway, it’s a great time to trot out my latest healthcare predictions. Perhaps one of the areas that healthcare’s transformation will be most evident is in the transfer of power across care settings. In the US, hospitals will lose a high number of orthopedic and cardiac procedures—and their corresponding profits—to ambulatory settings. Headline-grabbing trends like AI, big data and robotics are on the list, too, and although their individual impact on the sector will be meaningful, it likely won’t measure up to the hype. Finally, medtech will take advantage of the decade’s fresh start by modernizing its business approach and finally entering the digital age. Here’s how these five trends will alter the way that medtech companies do business and make decisions in the coming years.


>
Read More

Reversing Medtech Price Erosion

Posted by Brian Chapman on September 5, 2019

This blog post is the second in a two-part series about what’s behind price erosion in medtech and how to reverse it.

Medtech is dealing with forces that have been eroding profitability. As companies look to repair this price erosion, they’ll need to adopt a more comprehensive approach to pricing governance and execution, which includes leveraging data and analytics to improve their pricing and contracting strategies.


>
Read More

What’s Driving Medtech Price Erosion?

Posted by Brian Chapman on September 3, 2019

This blog post is the first in a two-part series about what’s behind price erosion in medtech and how to reverse it.

Medtech leaders today face several headwinds that are threatening to erode price and profitability. Some of these forces are external—like the professionalization of purchasing, provider consolidation, a changing buying center and increased focus on product value—but others are internal habits and mindsets that are long overdue for a change. In our next post, we’ll discuss how medtech leaders have begun to address these challenges, but before we do, let’s define their root causes.


>
Read More

Medtech Commercial Excellence is Evolving in Europe. Here’s What Industry Experts Are Saying.

Posted by Shaurya Aggarwal on June 17, 2019

Lukas Grabner co-wrote this post with Shaurya Aggarwal

Recently, we hosted a round table for European Medtech commercial excellence leaders to discuss the current state of their function. Overall, the group was enthusiastic about the impact they have been able to demonstrate, even with limited organizational investment; however, there was recognition of EU medtech‘s maturity and small scale relative to other industries such as pharmaceuticals. While the commercial excellence function is critical for organizational success, the path to realize that impact demands a strategic plan, close business collaboration, and a clear executive mandate.

During our conversation, we noticed three broad areas for opportunity: foundational structures, team setup and talent management.


>
Read More